Risperidone ODT Mylan

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Risperidone 4mg

Pieejams no:

Viatris Limited

SNN (starptautisko nepatentēto nosaukumu):

Risperidone 4 mg

Deva:

4 mg

Zāļu forma:

Orodispersible tablet

Kompozīcija:

Active: Risperidone 4mg Excipient: Aspartame Colloidal silicon dioxide Crospovidone Guar gum Iron oxide red Magnesium stearate Mannitol Microcrystalline cellulose Polacrilin

Receptes veids:

Prescription

Ražojis:

Mylan Laboratories Limited

Ārstēšanas norādes:

Indicated for the treatment of schizophrenia and other psychotic disorders. These include first episode pyschoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone also alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Risperidone also appears effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial response to treatment with this agent.

Produktu pārskats:

Package - Contents - Shelf Life: Blister pack, OPA/Al/PVC-Al in cardboard carton - 14 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 28 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 56 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, OPA/Al/PVC-Al in cardboard carton - 84 tablets - 36 months from date of manufacture stored at or below 25°C

Autorizācija datums:

2013-12-03